Literature DB >> 2981406

Circulating activated suppressor T lymphocytes in aplastic anemia.

N C Zoumbos, P Gascón, J Y Djeu, S R Trost, N S Young.   

Abstract

We studied the mechanism of hematopoietic suppression in aplastic anemia by means of two-color flow microfluorometric analysis of lymphocyte subpopulations and correlated the results with the occurrence in vitro of hematopoietic suppression and interferon production. In 12 patients with aplastic anemia a striking increase was observed in a population of "activated" suppressor T lymphocytes, which were defined by binding of both anti-Leu-2 and anti-HLA-DR monoclonal antibodies (patients with aplastic anemia, 6.8 +/- 3.2 per cent [mean +/- S.D.]; normal subjects, 1.7 +/- 1.3; patients given multiple transfusions, 2.5 +/- 1.7). Tac antigen expression, another surface marker of lymphocyte activation, was increased on suppressor lymphocytes in all five patients examined (patients with aplastic anemia, 31 +/- 17 per cent; normal subjects, 0.7 +/- 0.24; patients given multiple transfusions, 2.3 +/- 1.2). When Tac+ and Tac- cells were separated in a cell sorter, only Tac+ cells produced interferon. When lymphocytes of patients with aplastic anemia were cocultured with normal bone marrow, only the Tac+ cell fraction showed hematopoietic suppressor activity. In one patient, in vitro elimination of suppressor lymphocytes by use of OKT8 antibody abolished spontaneous interferon production by bone-marrow cells. These results suggest that activated suppressor lymphocytes producing interferon have a role in the pathogenesis of bone-marrow failure, and indicate the usefulness of defined lymphokine and phenotypic markers in the study of aplastic anemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981406     DOI: 10.1056/NEJM198501313120501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  48 in total

1.  T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia.

Authors:  Elena E Solomou; Keyvan Keyvanfar; Neal S Young
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  Clonal analysis of CD4+/CD8+ T cells in a patient with aplastic anemia.

Authors:  U Moebius; F Herrmann; T Hercend; S C Meuer
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

Review 3.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

4.  Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.

Authors:  R Gustafsson; T H Tötterman; L Klareskog; R Hällgren
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

5.  Immunological suppression after surgery in scoliosis patients.

Authors:  N Suzuki; O Kaneko; T Nakayama; Y Fukuiya; S Kuge; Y Fujimura
Journal:  Eur Spine J       Date:  1997       Impact factor: 3.134

6.  Peripheral blood lymphocyte subpopulations in patients with primary proliferative and secondary polycythaemia.

Authors:  J T Wilde; D Barnett; M J Forrest; A C Lawrence
Journal:  J Clin Pathol       Date:  1987-02       Impact factor: 3.411

7.  Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor.

Authors:  W Schwinger; C Urban; H Lackner; C Mache
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

Review 8.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

9.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

10.  Pure red cell aplasia in a patient with trisomy X chromosome abnormality and reactivated Epstein-Barr virus infection.

Authors:  Masanori Daibata; Hisanori Machida; Yuiko Nemoto; Hirokuni Taguchi
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.